Overview

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Status:
RECRUITING

Trial end date:
2028-10-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Phase:

PHASE3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

remibrutinib